Page last updated: 2024-10-28
hydroxyurea and Atheroma
hydroxyurea has been researched along with Atheroma in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Matsumoto, S | 1 |
| Ibrahim, R | 1 |
| Grégoire, JC | 1 |
| L'Allier, PL | 1 |
| Pressacco, J | 1 |
| Tardif, JC | 1 |
| Budoff, MJ | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Clinical Study Protocol No. VIA-2291-01, A Phase 2 Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging Study of the Effect of VIA-2291 on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event[NCT00358826] | Phase 2 | 191 participants (Actual) | Interventional | 2006-07-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) - Core Study
(NCT00358826)
Timeframe: Baseline and 12 weeks
| Intervention | mg/L (Median) |
|---|
| VIA-2291 25 mg | -0.2 |
| VIA-2291 50 mg | -0.1 |
| VIA-2291 100 mg | -0.3 |
| Placebo | -0.2 |
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) - MDCT Substudy
(NCT00358826)
Timeframe: Baseline and 24 weeks
| Intervention | mg/L (Median) |
|---|
| VIA-2291 25 mg MDCT Substudy | -0.4 |
| VIA-2291 50 mg MDCT Substudy | -0.2 |
| VIA-2291 100 mg MDCT Substudy | -0.4 |
| Placebo MDCT Substudy | 0.0 |
Change From Baseline in Leukotriene E4 (LTE4)
Urinary LTE4 is expressed in pg per mg Creatinine (pg/mg Cr) to normalize for renal excretion rate (NCT00358826)
Timeframe: Baseline and 12 weeks
| Intervention | pg/mg Cr (Least Squares Mean) |
|---|
| VIA-2291 25 mg | -26.8 |
| VIA-2291 50 mg | -38.6 |
| VIA-2291 100 mg | -56.5 |
| Placebo | 8.4 |
Change From Baseline in Mean Plaque Density
Plaque density is expressed in Hounsfield Units (HU) (NCT00358826)
Timeframe: Baseline and 24 weeks
| Intervention | HU (Least Squares Mean) |
|---|
| VIA-2291 25 mg | 19.11 |
| VIA-2291 50 mg | 7.39 |
| VIA-2291 100 mg | 12.22 |
| Placebo | 12.42 |
Change From Baseline in Noncalcified Plaque Volume
(NCT00358826)
Timeframe: Baseline and 24 weeks
| Intervention | mm^3 (Least Squares Mean) |
|---|
| VIA-2291 25 mg MDCT Substudy | -1.55 |
| VIA-2291 50 mg MDCT Substudy | -5.6 |
| VIA-2291 100 mg MDCT Substudy | 0.15 |
| Placebo MDCT Substudy | 2.83 |
Change From Baseline in Percent Stenosis
(NCT00358826)
Timeframe: Baseline and 24 weeks
| Intervention | Percentage (Least Squares Mean) |
|---|
| VIA-2291 25 mg | -0.11 |
| VIA-2291 50 mg | 11.45 |
| VIA-2291 100 mg | 2.36 |
| Placebo | 1.19 |
Change From Baseline on ex Vivo Leukotriene B4 Synthesis in Whole Blood
(NCT00358826)
Timeframe: Baseline and 12 weeks
| Intervention | pg/mL (Least Squares Mean) |
|---|
| VIA-2291 25 mg | -88126 |
| VIA-2291 50 mg | -95703 |
| VIA-2291 100 mg | -122668 |
| Placebo | -20843 |
Trials
1 trial available for hydroxyurea and Atheroma